AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

30/09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
28/26/28	€0.6940	+0.87%
25/26/25	€0.6880	-1.99%
24/26/24	€0.7020	-1.40%
23/26/23	€0.7120	-0.14%
22/26/22	€0.7130	-0.56%

Real-time Boerse Muenchen

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Boerse Muenchen 02:13:47 29/09/2026 am IST			5-day change	1st Jan Change
0.6940 ^EUR	+0.87%		-3.51%	-50.50%

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement

Market Cap	5.52Cr 6.28Cr 5.22Cr 4.73Cr 8.89Cr 602.6Cr 8.94Cr 63Cr 24Cr 307.57Cr 24Cr 23Cr 987.97Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.52Cr 6.28Cr 5.22Cr 4.73Cr 8.89Cr 602.6Cr 8.94Cr 63Cr 24Cr 307.57Cr 24Cr 23Cr 987.97Cr	EV / Sales 2026 *	46x	EV / Sales 2027 *	42.5x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	AB	Real-time
CBOE	ABp	Real-time
London S.E.	0Q77	Delayed
Tradegate	A8D	Real-time
Boerse Muenchen	A8D	Real-time
Deutsche Boerse AG	A8D	Delayed
CBOE	0Q77	Real-time
Börse Stuttgart	A8D	Delayed

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI

AB Science Share Price Boerse Muenchen

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
10/08	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
04/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

25/09	Agenda Zonebourse des résultats de sociétés : semaine du 28 septembre au 2 octobre 2026
24/08	AB Science : Franchissement de seuils et déclaration d'intention
17/08	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
17/08	AB Science procède au règlement-livraison de son placement privé
17/08	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

1 week	-3.51%
Current month	-1.29%
1 month	-6.90%
3 months	-20.46%
6 months	-41.10%
Current year	-50.50%

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	65	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+0.87%	-3.51%	-45.22%	-70.79%	6.24Cr
MERCK & CO., INC.	-0.06%	+1.24%	+89.27%	+43.05%	37TCr
MERCK KGAA	+2.56%	+6.62%	+29.88%	-11.02%	6.69TCr
HALOZYME THERAPEUTICS, INC.	-0.89%	+0.39%	+53.07%	+193.60%	1.29TCr
KYOWA KIRIN CO., LTD.	-0.93%	-0.44%	-2.69%	-16.04%	754.26Cr
SK BIOPHARMACEUTICALS CO., LTD.	+0.40%	-1.93%	-24.93%	-11.60%	437.87Cr
YUHAN CORPORATION	+0.81%	-1.58%	-34.87%	+3.48%	407.44Cr
BETTA PHARMACEUTICALS CO., LTD.	-1.08%	+1.04%	-29.63%	-15.59%	302.29Cr
SUPERNUS PHARMACEUTICALS, INC.	+4.55%	+6.19%	-5.17%	+56.05%	247.97Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.84%	-1.50%	-21.36%	-28.68%	190.99Cr
Average	+0.50%	-0.28%	+0.84%	+14.25%	5.23TCr
Weighted average by Cap.	+0.30%	+1.56%	+74.49%	+37.09%

	2026 *	2027 *
Net sales	12L 13.64L 11.34L 10.29L 19.33L 13Cr 19.43L 1.36Cr 52.42L 6.69Cr 51.22L 50.11L 21Cr	13L 14.78L 12.29L 11.15L 20.94L 14Cr 21.05L 1.47Cr 56.79L 7.24Cr 55.49L 54.29L 23Cr
Net income	-	-
Net Debt	-	-

1 week	0.67	0.72
1 month	0.67	0.75
3 years	0.51	4.4
5 years	0.51	13.56